GlassScriptPhysician profile
Evelyn Sarpong
NPI 1215644745
$1,518.63
in general payments reported to CMS, 2019-2025
22 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $191 · 2024: $657 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $373.52 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $182.05 | 2024-2025 | Camzyos, Cobenfy, Eliquis |
| Esperion Therapeutics, INC. | $134.36 | 2023-2025 | Nexletol |
| Amgen INC. | $129.58 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $121.31 | 2023-2025 | Verquvo |
| Pfizer INC. | $84.59 | 2023-2024 | |
| Edwards Lifesciences Corporation | $59.75 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $53.45 | 2023-2024 | Xarelto |
| Shockwave Medical, INC | $52.41 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $51.82 | 2024 | Andexxa |
| Lexicon Pharmaceuticals, INC. | $46.19 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $41.60 | 2025 | Uptravi, Opsumit |
| Vital Connect, INC | $26.98 | 2024 | Vitalpatch Rtm |
| Daiichi Sankyo INC. | $25.93 | 2024 | Injectafer |
| Atricure, INC. | $20.04 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.51 | 2024 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.77 | 2024 | Lifevest |
| Glaxosmithkline, LLC. | $16.67 | 2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $15.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.45 | 2025 | Jardiance |
| Heartflow, INC. | $14.45 | 2025 | |
| Novo Nordisk INC | $14.24 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Sarpong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.